Gregory Y H Lip Selected Research

Antithrombins

10/2021	Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study.
1/2018	Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA).
8/2017	The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.
12/2015	Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
9/2015	Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
3/2015	Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.
1/2015	Antidotes to non-vitamin K oral anticoagulants: necessary or not?
5/2014	Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
6/2013	Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
9/2012	New anticoagulant treatments to protect against stroke in atrial fibrillation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gregory Y H Lip Research Topics

Disease

849	Atrial Fibrillation 11/2022 - 01/2002
557	Stroke (Strokes) 11/2022 - 01/2002
438	Hemorrhage 11/2022 - 01/2002
152	Ischemic Stroke 09/2022 - 12/2004
147	Heart Failure 09/2022 - 11/2002
127	Hypertension (High Blood Pressure) 08/2022 - 07/2002
109	Thromboembolism 01/2022 - 05/2003
106	Embolism (Embolus) 10/2022 - 09/2004
106	Myocardial Infarction 09/2022 - 11/2002
94	Thrombosis (Thrombus) 07/2022 - 01/2002
83	Cardiovascular Diseases (Cardiovascular Disease) 04/2022 - 01/2002
62	Acute Coronary Syndrome 01/2022 - 12/2002
58	Inflammation (Inflammations) 01/2022 - 09/2002
48	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 12/2003
47	Vascular Diseases (Vascular Disease) 01/2022 - 06/2004
47	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2022 - 03/2011
44	Diabetes Mellitus 11/2021 - 08/2003
41	Cardiac Arrhythmias (Arrythmia) 04/2022 - 12/2002
37	Neoplasms (Cancer) 10/2022 - 09/2002
36	Venous Thromboembolism 09/2022 - 10/2002
34	Transient Ischemic Attack 05/2021 - 06/2008
31	Chronic Renal Insufficiency 01/2022 - 02/2004
22	Atherosclerosis 01/2022 - 02/2002
22	COVID-19 01/2022 - 01/2020
21	Peripheral Arterial Disease 08/2022 - 04/2003
18	Dementia (Dementias) 01/2022 - 10/2012
17	Heart Diseases (Heart Disease) 07/2022 - 02/2004
14	Coronary Disease (Coronary Heart Disease) 07/2022 - 03/2003
14	Fibrosis (Cirrhosis) 01/2022 - 05/2003
13	Systolic Heart Failure 01/2017 - 08/2004
12	Obesity 11/2021 - 09/2006
10	Cerebral Hemorrhage 09/2022 - 09/2011
10	Body Weight (Weight, Body) 01/2022 - 09/2006
9	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 12/2011
9	Type 2 Diabetes Mellitus (MODY) 01/2022 - 08/2004
9	ST Elevation Myocardial Infarction 08/2021 - 06/2009
9	Pulmonary Embolism 12/2020 - 01/2003

Drug/Important Bio-Agent (IBA)

441	AnticoagulantsIBA 11/2022 - 10/2003
310	Warfarin (Coumadin)FDA LinkGeneric 07/2022 - 01/2002
274	Vitamin K FDA Link 10/2022 - 09/2004
143	Dabigatran FDA Link 07/2022 - 03/2010
138	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 08/2002
106	apixabanIBA 07/2022 - 09/2008
103	RivaroxabanIBA 09/2022 - 03/2007
63	N(4)-oleylcytosine arabinosideIBA 09/2022 - 11/2013
61	edoxabanIBA 10/2022 - 01/2012
61	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2004
51	von Willebrand FactorIBA 01/2018 - 07/2002
48	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022 - 12/2003
44	Pharmaceutical PreparationsIBA 11/2022 - 01/2004
36	Clopidogrel (Plavix)FDA Link 08/2021 - 08/2002
33	P-SelectinIBA 01/2017 - 05/2002
29	omega-Chloroacetophenone (Mace)IBA 07/2022 - 02/2008
29	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 01/2006
29	C-Reactive ProteinIBA 01/2021 - 06/2003
25	Factor Xa InhibitorsIBA 01/2022 - 03/2007
24	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2013 - 02/2002
23	LipidsIBA 07/2022 - 08/2003
23	Interleukin-6 (Interleukin 6)IBA 01/2018 - 07/2003
22	CreatinineIBA 01/2022 - 02/2004
20	AntithrombinsIBA 10/2021 - 01/2005
20	E-SelectinIBA 01/2017 - 06/2003
19	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2022 - 04/2015
19	Anti-Arrhythmia AgentsIBA 01/2022 - 07/2004
18	fibrin fragment D (D-dimer)IBA 01/2021 - 01/2003
17	Brain Natriuretic Peptide (Natrecor)FDA Link 11/2021 - 09/2004
17	Fibrinogen (Factor I)FDA Link 01/2021 - 01/2003
17	Thromboplastin (Tissue Factor)IBA 01/2019 - 09/2002
16	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 11/2004
16	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021 - 11/2002
15	Enoxaparin (Lovenox)FDA LinkGeneric 01/2021 - 01/2006
14	FibrinIBA 01/2018 - 07/2003
13	AcenocoumarolIBA 03/2018 - 07/2011
11	CholesterolIBA 01/2022 - 08/2003
11	TicagrelorIBA 08/2021 - 01/2012
11	Heparin (Liquaemin)FDA LinkGeneric 01/2021 - 09/2004
11	Thrombin FDA Link 01/2018 - 12/2004
11	Matrix Metalloproteinases (MMPs)IBA 01/2012 - 01/2004
10	Antihypertensive Agents (Antihypertensives)IBA 01/2022 - 01/2003
10	Angiotensin Receptor AntagonistsIBA 10/2020 - 11/2002
10	AngiopoietinsIBA 08/2009 - 02/2004
9	idraparinuxIBA 01/2018 - 07/2011
9	angiogeninIBA 08/2013 - 12/2007
9	Tissue Inhibitor of Metalloproteinase-1IBA 01/2012 - 05/2003
9	CD40 Ligand (CD40L)IBA 08/2011 - 06/2004
8	DiureticsIBA 01/2022 - 09/2003
8	Dronedarone FDA Link 01/2022 - 05/2009
8	Digoxin (Digitek)FDA LinkGeneric 01/2022 - 12/2007

Therapy/Procedure

486	Therapeutics 11/2022 - 01/2002
81	Percutaneous Coronary Intervention 07/2022 - 12/2002
47	Electric Countershock (Cardioversion) 04/2022 - 08/2004
43	Stents 07/2022 - 02/2008
41	Secondary Prevention 04/2022 - 05/2003
40	Catheter Ablation 07/2022 - 12/2009
23	Drug Therapy (Chemotherapy) 11/2022 - 10/2003
16	Patient Readmission 01/2022 - 05/2011
10	Cardiac Rehabilitation 01/2022 - 09/2003
9	Defibrillators (Defibrillator) 01/2021 - 09/2009
9	Contraindications 10/2016 - 11/2002
8	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 01/2022 - 05/2008